Hanwha Aerospace has invested in the US startup Forge Nano, which boasts precision a nano-coating technology to extend the lifespan of secondary batteries. Forge Nano is led by Paul Lichty.
According to officials, this investment aims to expand synergies with the environmentally friendly propulsion system and energy storage system (ESS) business that can be applied to Urban Air Mobility (UAM) submarines and commercial vessels.
Hanwha Aerospace participated as a lead investor in Forge Nano’s Series C investment round, along with US investment firms Orion Infrastructure Capital (OIC), Catalus Ventures, and Ascent Funds. The total investment amount raised by Forge Nano is $50 million (approximately KRW 66.4 billion won).
Based on the raised investment, Forge Nano plans to not only invest in the development of existing material technologies but also commence the construction of a 1 GWh-scale secondary pilot plant this year. This pilot plant will utilize technologies applied to energy storage systems (ESS) for various sectors such as aviation, defense, and automotive industries.
Founded in 2011 at the University of Colorado’s research laboratory, Forge Nano is a specialist in the field of coating secondary battery materials to enhance their longevity. The company’s primary focus lies in the development of lithium-ion battery production facilities that incorporate nano-coating machines through pre-processing procedures. In recognition of its rapid growth, Forge Nano was honored as one of the notable companies in North America in the 2022 Deloitte Technology Fast 500™ ranking.
For inquiries and connections with Korean tech companies mentioned in this article, contact us at [email protected]. We’re here to facilitate valuable partnerships.
Also Read,
- Gyeonggi Province Selects 12 Startup Companies in Pangyo Techno Valley for Global Expansion Support Program
- Semiconductor Fabless Alliance Makes its Debut in Seongnam’s Pangyo Techno Valley
- MEDIAIPLUS, a Global Clinical Trial Data Platform participates in “Viva Technology 2023” in Paris, France
- Kainos Medicine Demonstrates Long-Term Effectiveness of its AIDS Treatment Drug ACC008 in Phase 3 Clinical Trial
Keep tab on latest news in the Korean startup ecosystem & follow us on LinkedIN, Facebook, and Twitter for more exciting updates and insights.
